302 results
CORRESP
LSTA
Lisata Therapeutics Inc
15 Jun 12
Correspondence with SEC
12:00am
environment in the People Republic of China (“PRC”), you plan to close your Regenerative Medicine business in PRC in 2012. With regard … to these businesses, please tell us the following:
Although in your Form 10-Q filed on May 11, 2012 you present your Regenerative Medicine-China segment
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
20 Jun 18
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
1:28pm
EXHIBIT 99.1
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina … Administration (“FDA”) has granted regenerative medicine advanced therapy (“RMAT”) designation to the Company’s late-stage CD34+ cell therapy program
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
20 Mar 13
Other Events
12:00am
Exhibit 99.1
NeoStem CEO's Letter to Shareholders
NEW YORK, March 19, 2013 (GLOBE NEWSWIRE) --
Dear NeoStem Shareholders,
Regenerative medicine … . The use of human VSELsTM for regenerative medicine presents the possibility of capturing the key advantages associated with embryonic stem cells
8-K
EX-99
LSTA
Lisata Therapeutics Inc
1 Sep 06
Consulting for Strategic Growth 1
12:00am
Cell Banking and Clinical Applications and the closing of financings. Regenerative treatments using adult stem cell therapies for numerous diseases … as well as radiation sickness and wound healing are developing rapidly as Americans and others focus on regenerative medicine. We are the first company
8-K
EX-99.2
9n0ca7d nh
12 Dec 05
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
wpswsx0 at
11 Mar 13
NeoStem Announces 2012 Year End Financial Results and Business Update
12:00am
8-K
hbazdahs 5yiodh
1 Feb 10
Regulation FD Disclosure
12:00am
8-K
EX-99.1
11oei5atnxrggidg5ijs
15 Aug 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
bhcp em3ewd
22 Jan 15
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors
12:00am
8-K
EX-99.1
298xuhumoxtf6uq 5l2
12 Jul 13
NeoStem Announces 1-for-10 Reverse Split
12:00am
8-K
EX-99.1
4sd2hiibc7
17 Oct 13
Regulation FD Disclosure
12:00am
8-K
tagrbsj 9rk
15 Aug 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99.2
i4xzdy7t94 58hb0g5r
6 Jan 12
NeoStem, Inc. (“NBS”) Investor Presentation January 2012
12:00am
8-K
EX-99.1
zl99lwpvn1ve373zz10z
9 Sep 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
bkhr2e3kqkmnt 05q
19 Sep 13
Regulation FD Disclosure
12:00am